Jailendra Singh
Stock Analyst at Truist Securities
(0.93)
# 4,000
Out of 5,149 analysts
192
Total ratings
28.7%
Success rate
-26.19%
Average return
Main Sectors:
Stocks Rated by Jailendra Singh
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| PGNY Progyny | Maintains: Buy | $34 → $28 | $17.52 | +59.82% | 11 | Mar 2, 2026 | |
| PRVA Privia Health Group | Maintains: Buy | $31 → $33 | $23.77 | +38.83% | 9 | Mar 2, 2026 | |
| EVH Evolent Health | Maintains: Buy | $10 → $6 | $3.51 | +70.94% | 9 | Feb 26, 2026 | |
| HIMS Hims & Hers Health | Reiterates: Hold | $37 → $18 | $15.82 | +13.78% | 12 | Feb 24, 2026 | |
| IQV IQVIA Holdings | Maintains: Buy | $290 → $245 | $173.96 | +40.84% | 19 | Feb 19, 2026 | |
| WAY Waystar Holding | Maintains: Buy | $51 → $38 | $26.58 | +42.96% | 4 | Feb 18, 2026 | |
| MEDP Medpace Holdings | Maintains: Hold | $555 → $539 | $465.38 | +15.82% | 7 | Feb 11, 2026 | |
| DOCS Doximity | Maintains: Buy | $62 → $37 | $26.97 | +37.19% | 10 | Feb 6, 2026 | |
| MDLN Medline | Initiates: Buy | $52 | $44.39 | +17.14% | 1 | Jan 12, 2026 | |
| ICLR ICON Public Limited Company | Downgrades: Hold | $231 → $222 | $108.70 | +104.23% | 11 | Jan 8, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $12 → $22 | $10.48 | +109.92% | 1 | Jan 8, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $35 → $36 | $12.37 | +191.03% | 7 | Sep 8, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $48 | $44.36 | +8.21% | 1 | Jun 16, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Hold | $10 → $9 | $5.10 | +76.47% | 16 | May 27, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Hold | $6.5 → $5.5 | $2.07 | +165.70% | 12 | Apr 10, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Hold | $12 → $7.5 | $5.15 | +45.63% | 7 | Apr 10, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $50 → $46 | $24.51 | +87.68% | 5 | Mar 18, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Hold | $261 → $210 | $185.91 | +12.96% | 7 | Jan 13, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $17 → $14 | $12.06 | +16.09% | 1 | Jul 2, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Hold | $6.4 → $6.5 | $0.57 | +1,045.58% | 8 | May 24, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $16 → $13 | $1.56 | +733.33% | 11 | May 4, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $30 → $24 | $1.16 | +1,968.97% | 2 | Feb 24, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $14 → $4 | $0.79 | +408.91% | 4 | Feb 8, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $60 → $58 | $226.35 | -74.38% | 2 | Feb 4, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underperform | $90 → $45 | $1.54 | +2,822.08% | 7 | Jan 7, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | $230 → $333 | $995.69 | -66.56% | 6 | Jan 7, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $10 → $9 | $2.00 | +350.00% | 2 | May 19, 2021 |
Progyny
Mar 2, 2026
Maintains: Buy
Price Target: $34 → $28
Current: $17.52
Upside: +59.82%
Privia Health Group
Mar 2, 2026
Maintains: Buy
Price Target: $31 → $33
Current: $23.77
Upside: +38.83%
Evolent Health
Feb 26, 2026
Maintains: Buy
Price Target: $10 → $6
Current: $3.51
Upside: +70.94%
Hims & Hers Health
Feb 24, 2026
Reiterates: Hold
Price Target: $37 → $18
Current: $15.82
Upside: +13.78%
IQVIA Holdings
Feb 19, 2026
Maintains: Buy
Price Target: $290 → $245
Current: $173.96
Upside: +40.84%
Waystar Holding
Feb 18, 2026
Maintains: Buy
Price Target: $51 → $38
Current: $26.58
Upside: +42.96%
Medpace Holdings
Feb 11, 2026
Maintains: Hold
Price Target: $555 → $539
Current: $465.38
Upside: +15.82%
Doximity
Feb 6, 2026
Maintains: Buy
Price Target: $62 → $37
Current: $26.97
Upside: +37.19%
Medline
Jan 12, 2026
Initiates: Buy
Price Target: $52
Current: $44.39
Upside: +17.14%
ICON Public Limited Company
Jan 8, 2026
Downgrades: Hold
Price Target: $231 → $222
Current: $108.70
Upside: +104.23%
Jan 8, 2026
Upgrades: Buy
Price Target: $12 → $22
Current: $10.48
Upside: +109.92%
Sep 8, 2025
Maintains: Buy
Price Target: $35 → $36
Current: $12.37
Upside: +191.03%
Jun 16, 2025
Initiates: Buy
Price Target: $48
Current: $44.36
Upside: +8.21%
May 27, 2025
Maintains: Hold
Price Target: $10 → $9
Current: $5.10
Upside: +76.47%
Apr 10, 2025
Maintains: Hold
Price Target: $6.5 → $5.5
Current: $2.07
Upside: +165.70%
Apr 10, 2025
Maintains: Hold
Price Target: $12 → $7.5
Current: $5.15
Upside: +45.63%
Mar 18, 2025
Maintains: Buy
Price Target: $50 → $46
Current: $24.51
Upside: +87.68%
Jan 13, 2025
Maintains: Hold
Price Target: $261 → $210
Current: $185.91
Upside: +12.96%
Jul 2, 2024
Maintains: Buy
Price Target: $17 → $14
Current: $12.06
Upside: +16.09%
May 24, 2024
Maintains: Hold
Price Target: $6.4 → $6.5
Current: $0.57
Upside: +1,045.58%
May 4, 2022
Maintains: Neutral
Price Target: $16 → $13
Current: $1.56
Upside: +733.33%
Feb 24, 2022
Maintains: Neutral
Price Target: $30 → $24
Current: $1.16
Upside: +1,968.97%
Feb 8, 2022
Downgrades: Neutral
Price Target: $14 → $4
Current: $0.79
Upside: +408.91%
Feb 4, 2022
Maintains: Neutral
Price Target: $60 → $58
Current: $226.35
Upside: -74.38%
Jan 7, 2022
Downgrades: Underperform
Price Target: $90 → $45
Current: $1.54
Upside: +2,822.08%
Jan 7, 2022
Upgrades: Outperform
Price Target: $230 → $333
Current: $995.69
Upside: -66.56%
May 19, 2021
Maintains: Neutral
Price Target: $10 → $9
Current: $2.00
Upside: +350.00%